Revenue (Details)			1 Months Ended					3 Months Ended		9 Months Ended		76 Months Ended
	Apr. 19, 2022 USD ($) item	Jan. 07, 2020 USD ($)	Dec. 31, 2019 USD ($)	Oct. 31, 2017 USD ($)	May 31, 2017 USD ($)	Jun. 30, 2016 USD ($)	May 31, 2016 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Grant Revenue
Revenue								$ 6,039,853	$ 501,567	$ 6,303,252	$ 1,499,706
Grant receivable								1,524,522		1,524,522		$ 1,524,522	$ 1,318,359
Allowable expenses incurred under NIH grant								40,000.00	0.0	40,000.00	30,000.00
Grant revenue
Grant Revenue
Revenue								58,860	501,567	322,259	$ 1,499,706
Allowable expenses incurred under NIH grant								40,470	$ 0
Grant revenue | Maximum
Grant Revenue
Amount Awarded From NIH Grant		$ 224,713
ANTHIM Vials
Grant Revenue
Number of vials to be delivered | item	3,000
Contract award	$ 6,000,000.0
Bad debt expense								0
ANTHIM Vials | Accounts receivable
Grant Revenue
Contract with customer, receivable, after allowance for credit loss, current	$ 6,000,000.0
Pelican Therapeutics, Inc.
Grant Revenue
Amount awarded from CPRIT grant							$ 15,200,000
Pelican Therapeutics, Inc. | Grant revenue
Grant Revenue
Revenue												15,200,000
Remaining grant amount receivable								1,500,000		1,500,000		1,500,000
Amount the company is required to match of each dollar of grant								0.50		0.50		0.50
Threshold amount for match of grant								1.00		1.00		1.00
Contribution to be made by Pelican								$ 7,600,000		$ 7,600,000		$ 7,600,000
Pelican Therapeutics, Inc. | Grant revenue | Maximum
Grant Revenue
Amount awarded from CPRIT grant						$ 15,200,000
Royalty percentage after threshold is met										1.00%
Pelican Therapeutics, Inc. | Grant revenue | Tranche 1
Grant Revenue
Revenue					$ 1,800,000
Pelican Therapeutics, Inc. | Grant revenue | Tranche 2
Grant Revenue
Revenue				$ 6,500,000
Pelican Therapeutics, Inc. | Grant revenue | Tranche 3
Grant Revenue
Revenue			$ 5,400,000